Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis
Yazarlar (7)
Celal Murat Hasanreisoğlu
Koç Üniversitesi, Türkiye
Koç Üniversitesi, Türkiye
Doç. Dr. Hüseyin Baran Özdemir Gazi Üniversitesi, Türkiye
Dr. Öğr. Üyesi Kaan ÖZKAN Kastamonu Üniversitesi, Türkiye
Zeynep Aktaş Atılım Üniversitesi, Türkiye
Prof. Dr. Hatice Tuba Atalay Gazi Üniversitesi, Türkiye
Prof. Dr. Şengül Özdek Gazi Üniversitesi, Türkiye
Prof. Dr. İhsan Gökhan Gürelik Gazi Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SCOPUS dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | Turk Oftalmoloji Dergisi-Turkish Journal of Ophthalmology | ||
| Dergi ISSN | 1300-0659 Dergi Bilgileri (2019) | ||
| Dergi Tarandığı Indeksler | TR DİZİN | ||
| Makale Dili | İngilizce | Basım Tarihi | 10-2019 |
| Cilt / Sayı / Sayfa | 49 / 5 / 250–257 | DOI | 10.4274/tjo.galenos.2019.81594. |
| Makale Linki | https://pubmed.ncbi.nlm.nih.gov/31650791/ | ||
| UAK Araştırma Alanları |
Sağlık Bilimleri
|
||
| Özet |
| Objectives To evaluate the long-term results of intravitreal dexamethasone implant (DEX) for noninfectious uveitis. Materials and Methods The study included 62 eyes of 44 patients treated with DEX implant due to noninfectious uveitis and followed up for at least a year. Best-corrected visual acuity (BCVA), central foveal thickness, intraocular pressure (IOP), vitreous haze score, indications, immunomodulatory therapy and steroid usage before/after injection, number of injections, and adverse events were analyzed retrospectively. Results Average follow-up was 20 months (range 12-64 months). The female/male ratio was 29/15. Mean age was 50 years (range 22-75 years). The most frequent uveitis etiologies were idiopathic (25 patients, 40.3%) and Behçet’s uveitis. (17 patients, 27.4%) The signedmost common indication for DEX injection was cystoid macular edema together with resistant vitreous haze (26 eyes, 41 … |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 27 |